logging in or signing up Analgesia bhatti106 Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 231 Category: Education License: All Rights Reserved Like it (0) Dislike it (0) Added: June 06, 2012 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript I: Pain and Analgesics: 1 I: Pain and Analgesi cs Pain ”an unpleasant sensory and emotional experience with actual or potential tissue damage or described in terms of such damage” (International Association for the Study of Pain, 1979) Analgesia absence of painPain pathways: 2 Pain pathways Specialized receptors = free nerve endings Stimulation Mechanical damage Extreme temperature Chemical irritation Two types of neurons A-delta: first pain, sharp C: second pain, dull Four distinct processes Transduction, transmission, modulation, perceptionTissue damage: 3 Tissue damage Release of chemical substances and enzymes (mediators) that alter the activity and sensitivity of sensory neurons Prostaglandins, leukotriens: sensitization of receptors Bradykinin and PGs: stimulate the neurons directly Histamine: pain, itching Result increase in nociceptor activity Hyperalgesia Neurogenic edemaPowerPoint Presentation: 4Dorsal horn: 5 Dorsal horn Wind-up neurotransmittors causing enhanced excitability and sensitization of dorsal horn cells Persist e nt changes Cause of allodynia (”touch becomes pain”) Prevented by pre-treatment with e.g opioidsPowerPoint Presentation: 6Perception: 7 Perception Somatosensory cortex, cingulate cortex Sensory discrimination Emotional response fear, anxiety and panic s ubjective experience Reticular formation Increased arousal Emotional response Somatic and autonomic motor reflexes Induction of biological and behavioural changesPerception cont.: 8 Perception cont. Higher vertebrates Anatomical components for perception of pain From the last third of embryonic development Primitive vertebrates Fish, reptiles, amphibians avoidance or escape behavior poorly developed cerebral cortexPharmacological treatment of pain: 9 Pharmacological treatment of pain Periphery-along axons-CNS Single treatment/polymodal Continuosly/ intermittently Regional ane NSAIDs Opioids NMDA-receptor agonists Alpha-2-receptor agonists Other agentsPowerPoint Presentation: 101. Regional anesthesia: 11 1. Regional anesthesia Lidocaine (lignocaine): Xylocain® Bupivacaine: Marcain ® Tricaine: MS-222® Preoperatively and postoperatively Underuse in small species Na + channels1. Regional anesthesia cont.: 12 Sensory, motor and sympathetic nerves Duration lipid solubility (bupivacaine > lidocaine) Adrenaline (1: 200,000): cave appendices Toxicity convulsions, hypotension, ventricular arrhythmia and myocardial depression Application Local infiltration, mucous membranes, eye, ear, around a nerve, intrapleurally, epidurally 1. Regional anesthesia cont.2. NSAIDs: 13 2. NSAIDs Non-steroidal anti-inflammatory drugs Reduce synthesis of PGs Cox inhibitors (cyclooxygenase) Diminish nociceptor activation Block peripheral sensitization Antipyretic Anti-hyperalgesic No sedation2. NSAIDs cont.: 14 Salicylates (aspirin) Ke toprofen: Romefen® Carprofen: Rimadyl ® PO, SC, IM Gastrointestinal ulceration and renal function disturbances, embryotoxic, prolong bleeding 2. NSAIDs cont.3. Opioids: 15 3. Opioids Spinal cord Decreasing neurotransmitter release Blocking postsynaptic receptors Activating inhibitory pathways Receptor subtypes mu> delta> kappa Supraspinal analgesia Peripheral analgesia (prevent nociceptor sensitization)3. Opioids cont.: 16 Morphine Fentanyl: Leptanal ®, Hypnorm® Sufentanil Burprenorphine: Temgesic ® Sedation PO, SC, IM, IP Side effects: respiratory depression, severe bradycardia, decreased gastric HCl secretion Less from delta agonists 3. Opioids cont.4. NMDA-receptor antagonists: 17 4. NMDA-receptor antagonists Spinal cord receptors Repetitive c-fiber activation Central hyperalgesia Not effective against acute inflammatory pain Effective against prolonged inflammatory pain Neuropathic and cancer pain Abolish the wind-up phenomenon Work in synergy with opioids Ketamine, tiletamine5. Alpha-2-agonists : 18 Xylaxine: Rompun® Medetomidine: Domitor® Receptors in the spinal cord and brain Activated by descending noradrenergic pathways Inhibit pre-synaptic calcium influx and neurotransmitter release IM, SC, IP, IV sedation, analgesia, muscle relaxation and anxiolysis Side effects Initial hypertension Hypotension Bradycardia Decreased cardiac output Depress insulin release Diuresis Hypothermia Specific antagonist atipamezole: Antisedan® 5. Alpha-2-agonists6. Other agents: 19 6. Other agents Sedatives and tranquillizers Diazepam, acepromazine, fluanisone Relieve anxiety, decrease stress Minimal respiratory and cardiovascular effects Hypotension, hypothermia GABA (enhancement), dopamine (blockade) Antagonist (flumazenil) SC, IM, IV Tricyclic antidepressants AmintryptillineII: Pain management: 20 II: Pain management Prevention: preemptive approach Recognition of pain Choice of substance Drug dose and durationDo animals experience pain?: 21 Do animals experience pain? No direct evidence Subtle behavioural responses Complex learning to avoid noxious stimuli Self-administration of analgesics in chronic pain conditions Response to analgesics Assessment centralWhy treat pain?: 22 Why treat pain? Legal and ethical reason Beneficial for the animal Beneficial for reserach Rapid return to normal function A higher survival rate Counteract physiological changes Thoracic and abdominal pain affect ventilation Reduction in food and water consumptionRecognition of pain: 23 Recognition of pain Prey animals mask pain Nocturnal species Signs to look for General appearance and condition Attitude, posture and movements Interactions with cage mates Reactions to manipulation Food and water consumption Production of faeces and urine Species-typical signs of pain and distress Procedure-specific signsPain during anaesthesia: 24 Pain during anaesthesia No consciousness-no pain perception (acute experiment) Sensory nerve activity and sensitization still possible Avoid unnecessary postoperative pain! Recognition of pain during surgery Spontanous movements Movemenets in reaction to nociceptive stimulation Respiration and puls frequency Blood pressure Withdrawal reflexesPostoperative pain: 25 Postoperative pain Peripheral sensitization Central sensitization Amplification of pain sensation Surgery Inflammatory pain Neuropathic pain Prevention by preemptive analgesiaDrug delivery: 26 Drug delivery Oral delivery Dosing Consumption Degradation NSAIDs Aspirin carprofen Opioids buprenorphine Parenteral delivery S/c, i/p, i/v, sublingual, rectalPowerPoint Presentation: 27 Drug Mouse Rat Guinea pig morphine 2-5 mg/kg SC, 4 hourly 2-5 mg/kg SC 4 hourly 2-5 mg/kg SC 4 hourly butorphanol 1-2 mg/kg SC 4 hourly 1-2mg/kg SC 4 hourly 2 mg/kg SC buprenorphine 0.05-0.1 mg/kg SC 8-12 hourly 0.01-0.05 mg/kg SC or IV 0.1-0.25 mg/kg by mouth 8-12 hourly 0.05 mg/kg SC 8-12 hourly carprofen 5 mg/kg SC or by mouth 24 hourly 5 mg/kg SC or by mouth 24 hourly ketoprofen 5 mg/kg SC or by mouth 24 hourly ibuprofen 30 mg/kg by mouth 24 hourly 15 mg/kg by mouth 24 hourly lidocaine 4 mg/kg or 0.4 ml/kg of a 1% solution bupivacaine 1-2 mg/kg or 0.4-0.8 ml/kg of a 0.25% solution amitriptyline 1.2-5 mg/kg SC or IP 3-12 hourly 1-10 mg/kg SC or IP 3-12 hourly imipramine 2.3 mg/kg SC or IP 12-24 hourly 10 mg/kg SC or IP 12-24 hourlyUse of local anaesthetics: 28 U se of local anaesthetics Topical, local infiltration, nerve block Skin, eye, ear canal, epidurally, periost, Reduction of anesthetic needs Post-operative analgesia Maximum dose for lidocaine: 4mg/kg bupivacaine: 2mg/kgPowerPoint Presentation: 29Fish anaeshthesia: 30 Fish anaeshthesia MS-222 (tricaine)Use of NSAIDs: 31 U se of NSAIDs For mild-moderate pain Acute and chronic pain When opioids are contraindicated Preemptively before inhalation or injection anaeshetsia: carprofen In combination with local anaesthetics or opioids for severe postoperative pain Not in pregnant animalsMain use of opioids: 32 Main use of opioids Preemptive analgesia and sedation Before inhalation anesthesia Before pentobarbital aneshtesia Not before other injectables Intraoperative pain relief (fentanyl) With pentobarbital for acute experiments in pigs Pig cardiac protocols Rodent anesthesia Hypnorm ® (fluanisone + fentanyl) Postoperative pain relief Buprenorphine (Temgesic ® ) after Hypnorm or ketamine combinations Peak duration after 30minManagement of postoperative pain: 33 Management of postoperative pain Preemptive analgesia Good surgical technique Sterile technique Supportive therapy Soft food Long drinking nipples Soft bedding Warm environment Avoid social isolationManagement of postoperative pain cont. : 34 Minor procedures single dose of an opioid or NSAID sufficient (preoperatively when possible) More invasive surgery Continue treatment for up to 24-36h After major surgery Continue analgesic administration for 36-72 hours Combination therapy Opioid NSAID Local analgesia Management of postoperative pain cont.Examples of analgesic treatment: 35 Examples of analgesic treatment Implantation of brain canula rat: Preemptive buprenorphine 0,05mg/kg Isoflurane anestesia Local infiltration with bupivacaine Ovarioectomy mouse Ketamine/medetomidine ane Buprenorphine towards the end of the procedureExamples of analgesic treatment cont. : 36 Arthrodesis lumbar spine rabbit Preemptive carprofen EMLA cream ear Induction of aneasthesia with propofol Maintainance with isoflurane anesthesia Local infiltration with bupivacaine Buprenorphine before recovery Feeding with baby food (carrot, apple) Fluids i/v Continuation of bup for 24-48h and NSAID for 72 or more h Examples of analgesic treatment cont.PowerPoint Presentation: 37PowerPoint Presentation: 38PowerPoint Presentation: 39PowerPoint Presentation: 40 You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.